645 related articles for article (PubMed ID: 17337254)
1. The PPARgamma ligand, rosiglitazone, reduces vascular oxidative stress and NADPH oxidase expression in diabetic mice.
Hwang J; Kleinhenz DJ; Rupnow HL; Campbell AG; Thulé PM; Sutliff RL; Hart CM
Vascul Pharmacol; 2007 Jun; 46(6):456-62. PubMed ID: 17337254
[TBL] [Abstract][Full Text] [Related]
2. Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.
Sorrentino SA; Bahlmann FH; Besler C; Müller M; Schulz S; Kirchhoff N; Doerries C; Horváth T; Limbourg A; Limbourg F; Fliser D; Haller H; Drexler H; Landmesser U
Circulation; 2007 Jul; 116(2):163-73. PubMed ID: 17592079
[TBL] [Abstract][Full Text] [Related]
3. Suppression of retinal peroxisome proliferator-activated receptor gamma in experimental diabetes and oxygen-induced retinopathy: role of NADPH oxidase.
Tawfik A; Sanders T; Kahook K; Akeel S; Elmarakby A; Al-Shabrawey M
Invest Ophthalmol Vis Sci; 2009 Feb; 50(2):878-84. PubMed ID: 18806296
[TBL] [Abstract][Full Text] [Related]
4. A nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist reverses endothelial dysfunction in diabetic (db/db-/-) mice.
Howarth AG; Wiehler WB; Pannirselvam M; Jiang Y; Berger JP; Severson D; Anderson TJ; Triggle CR
J Pharmacol Exp Ther; 2006 Jan; 316(1):364-70. PubMed ID: 16249369
[TBL] [Abstract][Full Text] [Related]
5. Increased oxidative stress in the streptozotocin-induced diabetic apoE-deficient mouse: changes in expression of NADPH oxidase subunits and eNOS.
Ding H; Hashem M; Triggle C
Eur J Pharmacol; 2007 Apr; 561(1-3):121-8. PubMed ID: 17292348
[TBL] [Abstract][Full Text] [Related]
6. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
[TBL] [Abstract][Full Text] [Related]
7. Rosiglitazone increases PPARgamma in renal tubular epithelial cells and protects against damage by hydrogen peroxide.
Sommer M; Wolf G
Am J Nephrol; 2007; 27(4):425-34. PubMed ID: 17622750
[TBL] [Abstract][Full Text] [Related]
8. Evidence that nitric oxide inhibits vascular inflammation and superoxide production via a p47phox-dependent mechanism in mice.
Harrison CB; Drummond GR; Sobey CG; Selemidis S
Clin Exp Pharmacol Physiol; 2010 Apr; 37(4):429-34. PubMed ID: 19843095
[TBL] [Abstract][Full Text] [Related]
9. Tumor necrosis factor-alpha induces endothelial dysfunction in Lepr(db) mice.
Gao X; Belmadani S; Picchi A; Xu X; Potter BJ; Tewari-Singh N; Capobianco S; Chilian WM; Zhang C
Circulation; 2007 Jan; 115(2):245-54. PubMed ID: 17200442
[TBL] [Abstract][Full Text] [Related]
10. Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone.
Larsen PJ; Lykkegaard K; Larsen LK; Fleckner J; Sauerberg P; Wassermann K; Wulff EM
Eur J Pharmacol; 2008 Oct; 596(1-3):173-9. PubMed ID: 18761337
[TBL] [Abstract][Full Text] [Related]
11. Ezetimibe ameliorates cardiovascular complications and hepatic steatosis in obese and type 2 diabetic db/db mice.
Fukuda M; Nakamura T; Kataoka K; Nako H; Tokutomi Y; Dong YF; Yasuda O; Ogawa H; Kim-Mitsuyama S
J Pharmacol Exp Ther; 2010 Oct; 335(1):70-5. PubMed ID: 20651026
[TBL] [Abstract][Full Text] [Related]
12. Peroxisome proliferator-activated receptor-γ activation reduces cyclooxygenase-2 expression in vascular smooth muscle cells from hypertensive rats by interfering with oxidative stress.
Martín A; Pérez-Girón JV; Hernanz R; Palacios R; Briones AM; Fortuño A; Zalba G; Salaices M; Alonso MJ
J Hypertens; 2012 Feb; 30(2):315-26. PubMed ID: 22179086
[TBL] [Abstract][Full Text] [Related]
13. Toll-like receptor 4 mutation protects obese mice against endothelial dysfunction by decreasing NADPH oxidase isoforms 1 and 4.
Liang CF; Liu JT; Wang Y; Xu A; Vanhoutte PM
Arterioscler Thromb Vasc Biol; 2013 Apr; 33(4):777-84. PubMed ID: 23413427
[TBL] [Abstract][Full Text] [Related]
14. Keratinocyte-derived vascular endothelial growth factor biosynthesis represents a pleiotropic side effect of peroxisome proliferator-activated receptor-gamma agonist troglitazone but not rosiglitazone and involves activation of p38 mitogen-activated protein kinase: implications for diabetes-impaired skin repair.
Schiefelbein D; Seitz O; Goren I; Dissmann JP; Schmidt H; Bachmann M; Sader R; Geisslinger G; Pfeilschifter J; Frank S
Mol Pharmacol; 2008 Oct; 74(4):952-63. PubMed ID: 18599600
[TBL] [Abstract][Full Text] [Related]
15. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
Yu J; Jin N; Wang G; Zhang F; Mao J; Wang X
Metabolism; 2007 Oct; 56(10):1396-401. PubMed ID: 17884451
[TBL] [Abstract][Full Text] [Related]
16. NO-mediated regulation of NAD(P)H oxidase by laminar shear stress in human endothelial cells.
Duerrschmidt N; Stielow C; Muller G; Pagano PJ; Morawietz H
J Physiol; 2006 Oct; 576(Pt 2):557-67. PubMed ID: 16873416
[TBL] [Abstract][Full Text] [Related]
17. Rosiglitazone reduces glucose-induced oxidative stress mediated by NAD(P)H oxidase via AMPK-dependent mechanism.
Ceolotto G; Gallo A; Papparella I; Franco L; Murphy E; Iori E; Pagnin E; Fadini GP; Albiero M; Semplicini A; Avogaro A
Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2627-33. PubMed ID: 17916771
[TBL] [Abstract][Full Text] [Related]
18. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, prevents microparticle-induced vascular hyporeactivity through the regulation of proinflammatory proteins.
Tesse A; Al-Massarani G; Wangensteen R; Reitenbach S; Martínez MC; Andriantsitohaina R
J Pharmacol Exp Ther; 2008 Feb; 324(2):539-47. PubMed ID: 18039959
[TBL] [Abstract][Full Text] [Related]
19. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
Kim MK; Chae YN; Kim HS; Choi SH; Son MH; Kim SH; Kim JK; Moon HS; Park SK; Shin YA; Kim JG; Lee CH; Lim JI; Shin CY
Arch Pharm Res; 2009 May; 32(5):721-7. PubMed ID: 19471887
[TBL] [Abstract][Full Text] [Related]
20. Activation of natriuretic peptide receptor-C attenuates the enhanced oxidative stress in vascular smooth muscle cells from spontaneously hypertensive rats: implication of Gialpha protein.
Saha S; Li Y; Lappas G; Anand-Srivastava MB
J Mol Cell Cardiol; 2008 Feb; 44(2):336-44. PubMed ID: 18162186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
